

October 12, 2015

Dear Editor in Chief and peer reviewers,

According to the invitation letter of your journal sent to me, ID number 02941657 since last November 2014, and I accepted to write the manuscript for Minireviews.

Recently, I submit manuscript no 21880 titled **“Correlation of *Helicobacter pylori* and Interleukin-8 mRNA Expression in high risk gastric cancer population prediction”**

It was accepted to revise and publish in WJCO. Therefore, please, view my replies to the peer reviewer in pages attached here with.

- 1) The author should address more information about IL-8 mRNA, how it works and what significance to predict?

Answer: We added the recent information of preliminary result on our analysis study and relative risk study. However, in this study we criticized on the 2 risk factors that we demonstrated that the level of IL-8 mRNA expression appeared higher in cancer population and relative risk demonstrated in table2, 3 and table 5.

- 2) In “Introduction” part, author had introduced the relationship between IL-8 mRNA and GC, please, give more details or reasons about this. Why IL-8mRNA may be a useful prognostic risk marker for gastric cancer

Answer: As we mention on our recent study, we reviewed that it was arising in more than 70-80% of gastric cancer cases, and the level of IL-8 mRNA expression has much variation allowed the histopathology and in the same advance stage. Therefore, we suspected that it may be useful for later study on prognostic risk marker for gastric cancer. (We are also during ongoing prognostic study, but do not demonstrate the result in this paper)

- 3) In the “Material and method” part, it is a retrospective cohorts, author should present exclusion and inclusive criteria.

Answer: We added the information as in page 3

- 4) It might be interesting to analysis IL-8 expression level in different stage and different histologic grades, in order to demonstrate whether IL-8 is more sensitive than *H.pylori* in different stage and grade gastric cancer.

Answer: We have non-normal distribution of gastric cancer because of very less number of early stage cases, and the sample size could not reach for statistical calculation. However, we are during another project and ongoing more sample size collection.

For the histologic grade we had ever reported on different of level for good and poor prognostic histologic type in our recent paper. The mean level is higher for the poorly differentiated type with significant statistically difference than in well differentiate type in the same stage in both Thai and Japanese gastric cancer. (Reference number 14)

5) As the author address in table 2, author chose IL-8 RAW RQ 100 as a bound, please, explain this. Is it from literature or it is just your experience in Thailand?

Answer: There are our experiments and see the population frequencies at the point of difference after many cut off points were done on statistical method. We selected the best range that we could see the significant difference between benign and cancer population. There is no other literature that measured and make a reference in clinical cases before.

6) About the “Result” part, author should add more evidence why this test is the most useful for prediction in the male group. If it is important for the result.

Answer: We added the table 4 to show the result of IL-8 mRNA expression those get along with increasing likelihood ratio when they are male. The prediction is more precise in this group of population.

7) In Figure 1’ AuROC of IL-8 mRNA expression with H.pylori I prediction of gastric cancer” It is better to add one curve on *H.pylori* infection alone in prediction of gastric cancer.

Answer: We had already added the figures as your suggestion. We separated figures to clear of each factor as demonstrated in figure1 and 2, and then again compared them in figure 3.

I wish this paper would be useful for medical person, research scientists, or one who research and is interested in gastric cancer biomarker search for future integrative diagnosis and treatment.

Thank you and appreciate for this opportunity and your great contribution.

With best regards,

Sirikan Limpakan( Yamada), MD, PhD, FRCS(T)

Division Chief of Gastrointestinal Surgery and Endoscopy

Department of Surgery

Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand 50200

Tel: +66-816716737, FAX: +66-53-94-6139

E-mail: siyamada@yahoo.com